Johnson & Johnson: Hypertension, Pulmonary trials

The registry lists 30 Hypertension, Pulmonary studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 13 have results posted.

Early Phase 1 2Phase 1 1Phase 2 9Phase 3 14Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 3
• A Study of Selexipag in Participants Who Participated in a Previous Selexipag StudyCompletedNCT04565990Phase 3Results posted
• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionActive, not recruitingNCT04175600Phase 3Results posted
• A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral SelexipagTerminatedNCT03942211Phase 2Results posted
• A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional TreatmentTerminatedNCT03689244Phase 3Results posted
• Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device ImplantationCompletedNCT02554903Phase 2Results posted
• Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular DysfunctionCompletedNCT02070991Phase 2Results posted
• Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionCompletedNCT02060721Phase 2Results posted
• Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionCompletedNCT02021292Phase 2Results posted
• Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT01437878Phase 2Results posted
• Persistent Pulmonary Hypertension of the NewbornTerminatedNCT01389856Phase 3Results posted
• The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 SettingTerminatedNCT00467896Phase 2Results posted
• Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedNCT00319111Phase 3Results posted
• The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial HypertensionTerminatedNCT00302211Phase 3Results posted
• A Study of Macitentan in Children Below 2 Years of AgeWithdrawnNCT05731492Phase 1
• A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance ImagingCompletedNCT04480723Early Phase 1
• A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)CompletedNCT04193046Early Phase 1
• A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).TerminatedNCT03809650Phase 3
• A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.CompletedNCT03422328Phase 3
• Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)TerminatedNCT00706082
• Pulmonary Artery Remodelling With BosentanCompletedNCT00595049Phase 4
• REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease ManagementCompletedNCT00370214
• A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET StudyTerminatedNCT00360087Phase 3
• Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary HypertensionCompletedNCT00313222Phase 3
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)TerminatedNCT00313196Phase 3
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)TerminatedNCT00310830Phase 3
• Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary FibrosisCompletedNCT00109681Phase 2
• Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class IICompletedNCT00091715Phase 3
• Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT00086463Phase 2
• The Effect of Tracleer® on Male FertilityCompletedNCT00082186Phase 4